Publications: 236 in 2026-04. -17.4% share of all MeSH-indexed PubMed records vs the same month last year (293 in 2025-04).
PublicationsPubMed
2362026-04
-17.4% share of all MeSH-indexed PubMed records vs same month last year (293 in 2025-04)provisional · settling
0.21% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 17 in 2026-09. -15.0% vs the same month last year (20 in 2025-09).
Clinical trialsClinicalTrials.gov
172026-09
-15.0% vs same month last year (20 in 2025-09)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 0 in 2026-09. No percentage shown. No percentage shown: both months are under 15 records. The count is ranked in its own history instead. NIH grants: latest count 0 is in the 34th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
02026-09
34th percentilein its typical range, versus 16-mo window (2025 to 2026)low volume
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 72 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 72 is in the 59th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
722026-09
59th percentilein its typical range, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 21 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 21 is in the 31st percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
212026-09
31st percentilein its typical range, versus 16-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 236 is in the 70th percentile, running high, versus 320 months since 2000.
70thpercentile
running high
236/mo · higher than 70% of 320 months since 2000
Clinical trials
Clinical trials: latest count 17 is in the 92nd percentile, near its historical high, versus 316 months since 2000.
92ndpercentile
near its historical high
17/mo · higher than 90% of 316 months since 2000
NIH grantsprovisional
NIH grants: latest count 0 is in the 34th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
34thpercentile
in its typical range
0/mo · higher than 0% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 72 is in the 59th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
59thpercentile
in its typical range
72/mo · higher than 50% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 21 is in the 31st percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
31stpercentile
in its typical range
21/mo · higher than 25% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 316 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 817/mo
Clinical trials2000 to 2026 · 316 mopeak 32/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 3/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 108/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 36/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-08..2026-07
3%of works have an industry affiliation
Inserm263
University of California San Diego252
Shanghai Jiao Tong University239
Wenzhou Medical University231
Capital Medical University227
Clinical trials
Lead sponsors · 2023-10..2026-09
35%industry-led in 2026-09
Assiut UniversityAcademic/other26
Sohag UniversityAcademic/other10
Cairo UniversityAcademic/other9
Tanta UniversityAcademic/other9
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisAcademic/other8
NIH grants
Funded institutions · 2025-07..2026-08
9awards in window
JOHNS HOPKINS UNIVERSITYMD · $2M · U242
NEW YORK UNIVERSITY SCHOOL OF MEDICINENY · $1.7M · R012
VIRGINIA COMMONWEALTH UNIVERSITYVA · $500K · U012
UNIVERSITY OF CALIFORNIA, SAN DIEGOCA · $500K · U012
HARRY S. TRUMAN MEMORIAL VA HOSPITALMO · $0 · IK61
Patents
Applicants · 2025-06..2026-09
ELI LILLY AND COMPANY17
Regeneron Pharmaceuticals, Inc.15
Novartis AG13
Alnylam Pharmaceuticals, Inc.12
Novo Nordisk A/S11
Preprints
Corresponding institutions · 2025-06..2026-09
University of Pennsylvania6
Yunnan University5
Beth Israel Deaconess Medical Center, Harvard Medical School3
2026-09-28biorxivDepartment of Nutritional Sciences and Toxicology, University of California Berkeley, California 94720, United States
Organizations only. No person data.
Would you read a monthly digest for MASH / NASH?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for MASH / NASH. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in MASH / NASH.
How we map "MASH / NASH"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Non-alcoholic Fatty Liver Disease"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10
ConditionSearch: nonalcoholic steatohepatitis OR NASH OR MASH OR MASLD OR nonalcoholic fatty liver disease OR metabolic dysfunction-associated steatohepatitis OR metabolic dysfunction-associated steatotic liver disease